论文部分内容阅读
目的:探讨乌梅丸联合美沙拉嗪治疗溃疡性结肠炎的临床疗效。方法:选取70例溃疡性结肠炎患者,随机分为对照组和观察组各35例,对照组患者采用美沙拉嗪治疗,观察组患者采用乌梅丸联合美沙拉嗪治疗,2个疗程后比较两组患者的治疗效果、症状积分、炎症指标等。结果:观察组总有效率为94.29%,显著高于对照组的74.29%,差异有统计学意义(P<0.05);观察组腹泻、腹痛、黏液脓血、里急后重等症状积分明显优于对照组,差异有统计学意义(P<0.05);观察组IL-1β、TNF-α、CRP等炎症指标均较对照组明显改善,差异有统计学意义(P<0.05)。结论:乌梅丸联合美沙拉嗪治疗溃疡性结肠炎疗效显著,能够快速改善临床症状,控制炎症,具有积极的临床意义。
Objective: To investigate the clinical efficacy of WuMei Wan combined with mesalazine in the treatment of ulcerative colitis. Methods: Seventy patients with ulcerative colitis were randomly divided into control group and observation group, with 35 cases in control group and mesalazine group. Patients in observation group were treated with Wumei Pills and mesalazine. After two courses of treatment, Group of patients with treatment, symptom score, inflammation indicators. Results: The total effective rate in the observation group was 94.29%, which was significantly higher than that in the control group (74.29%), the difference was statistically significant (P <0.05). The score of symptom such as diarrhea, abdominal pain, (P <0.05). The inflammation indexes of IL-1β, TNF-α and CRP in the observation group were significantly improved compared with the control group, the difference was statistically significant (P <0.05). Conclusion: Wumei pill combined with Mesalazine for the treatment of ulcerative colitis has obvious curative effect, can rapidly improve clinical symptoms and control inflammation, and has a positive clinical significance.